US EditionNovo Nordisk shares tumble as CEO warns it will get worse before it gets better
- Novo Nordisk on Tuesday said sales and adjusted operating profit could decline up to 13% this year, citing heavy U.S. price pressure and competition.
- Policy and market shifts — including MFN pricing — have lowered realised prices and patent losses for semaglutide, while Eli Lilly's tirzepatide and copycat drugs cut U.S. Wegovy market share.
- Accounting adjustments reveal a 14% drop in operating profit to 31.7 billion crowns, impacted by a $4.2 billion rebate reversal, as of February 3, 2026.
- Investors will tune into the Feb 4 conference call at 13.00 CEST, as Novo's U.S.-listed shares fell 12% after the earlier-than-expected earnings statement, according to CEO Mike Doustdar.
- As GLP-1 volumes expand, the company expects adjusted sales growth and adjusted operating profit growth at CER to decline between-5% and-13%, betting on the Wegovy pill and CagriSema to regain U.S. share.
53 Articles
53 Articles
The actions Novo Nordisk, the producer of Ozempic and Wegovy medicinal products, were completed by 20% on Wednesday, after the Danish pharmaceutical giant warned that it would be faced with price pressures “without prior” in 2026,...
The shares of Novo Nordisk, a manufacturer of popular slimming drugs Ozempic and Wegovy, plummet this Wednesday after the company surprised investors by predicting a sharp drop in sales, which shows an intensification of the price war on drugs against obesity.Continue reading
Once they were cashier hitters, now the Danish pharmaceutical company has fallen back in the case of weight loss products. A deal with the Trump administration is also causing pressure.
Novo Nordisk's shock 2026 guidance points to obesity battle heating up
Danish obesity drug giant Novo Nordisk is set to be punished by investors on Wednesday after it gave a far bleaker-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as prices come under pressure.
The Ozempic manufacturer is collapsing on the stock market. Novo Nordisk falls 18 percent. This means that 450 billion has gone up in smoke.
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
